logo

The disruptive personalized machine-based genetic counseling platform

Sector: Residential • Location: Israel

Source: EU Funding & Tenders Portal

Project
Ended

The promise of personalized medicine will soon materialize. However, this revolution will require genetic counsellors as key professional to facilitate patients´ informed decision-making. However, there are just 7,000 worldwide, insufficient to fulfil the ever-growing demand for these services (>40 million people tested in 2018). Likewise, health care organizations cannot implement genetic counsel

Project Information FAQ

Project Information

3 Q
The project “The disruptive personalized machine-based genetic counseling platform” is an infrastructure initiative in the Residential sector, located in Israel. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

The promise of personalized medicine will soon materialize. However, this revolution will require genetic counsellors as key professional to facilitate patients´ informed decision-making. However, there are just 7,000 worldwide, insufficient to fulfil the ever-growing demand for these services (>40 million people tested in 2018). Likewise, health care organizations cannot implement genetic counselling (GC) as a tool to help patients understand, adapt and adjust to the medical and psychological consequences of their genetic tests results. Innovative automated solutions are needed to fully exploit the benefits from the upcoming genomic revolution to overcome, not just the shortage but also expensive, time consuming and not scalable current GC approach. At Igentify Ltd, an Israeli startup home to 32 highly-skilled individuals, we have created the first clinically-approved Igentify: A 4 module-based machine learning digital platform automating all stages from the GC process, starting from enrolment of the patient into the system, until the delivery of customized machine generated GC. Igentify incorporates 2 features simplifying and making scalable GC: (1) A set of algorithms analysing all genetic-related parameters (e.g. ethnicity, carrier frequency, medical history, lifestyle, etc.) to profile the individual as low or high-risk. (2) A revolutionary audio-visual asset generation algorithm that autonomously creates dynamic audio-visual content customized for patients, explaining all information in an educational way. We have commercial agreements with early adopters, including Northwell Health, Gene by Gene, Kaplan Medical Center or Meudehet, confirming Igentify´s business opportunity. We expect to gain a 4% market share within the global genetic testing market (€16.7 billion valuation by 2024, CAGR of 12.2%, period 2018-2024). This will translate into a revenue of € 104.06 M in 2026 (ROI of 7.04), while creating 150 jobs.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data